Apart from acute infections, microorganisms may also induce or perpetuate chronic inflammatory diseases and reversible or irreversible proliferation of various cells in the gastrointestinal tract (the extreme being adenocarcinoma and lymphoma). Helicobacter pylori is not only involved in the pathogenesis of lymphoma and gastric adenocarcinoma. The steps and mechanisms of the carcinogenic process involve host predisposition, environmental factors, and strain virulence. The steps of lymphoma genesis include chronic inflammation, acquisition of mucosa-associated lymphoid tissue in the stomach, proliferation of the B lymphocytes in an inflammatory context, acquisition of genetic anomalies and dysregulation of the NF-ĸB pathway. The role of Campylobacter jejuni in immunoproliferative small bowel disease has also been shown and eradication of this bacterium can cure the lymphoma at its early stage. The evidence for the role of some bacteria in colon cancer development is discussed. Opportunistic pathogens are detected in the stools or mucosa of a proportion of subjects with Crohn’s disease. They include Mycobacterium avium paratuberculosis, adherent invasive Escherichia coli, and Clostridium difficile. A dysbiosis has been repeatedly observed in patients with inflammatory bowel disease. Instability of the dominant microbiota and decreased biodiversity (especially in the firmicutes phylum) are major characteristics. The decrease of Faecalibacterium prausnitzii seems to have a prognostic value to predict relapse of Crohn’s disease after surgery. Finally, important perspectives are opened by new tools such as metagenomics and metabolomics of the gastrointestinal ecosystems. Major tracks concern irritable bowel syndrome, colon cancer and obesity.

Keywords:
Bacteria, Bacteria-induced lymphoma, Bacteria-induced adenocarcinoma, Helicobacter pylori, Crohnߣs disease, Ulcerative colitis
1.
Doré J, Corthier G: The human intestinal microbiota. Gastroenterol Clin Biol 2010;34(suppl 1):S7–S15.
2.
Preidis GA, Versalovic J: Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009;136:2015–2031.
3.
Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D: Whipple’s disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 2008;8:179–190.
4.
Cover TL, Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology 2009;136:1863–1873.
5.
Herrera V, Parsonnet J: Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect 2009;15:971–976.
6.
Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD: Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267–1271.
7.
Sagaert X, Van Cutsem E, De Hertogh G, Geboes K, Tousseyn T: Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol 2010;7:336–346.
8.
Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdörffer E: Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000;118:821–828.
9.
Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, Bengoufa D, Feuillard J, Lavergne A, Gordon JI, Berche P, Guillevin L, Lortholary O: Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239–248.
10.
Newman JV, Kosaka T, Sheppard BJ, Fox JG, Schauer DB: Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice. J Infect Dis 2001;184:227–230.
11.
Jordane B, Nguyen IS, Pini A, Gossé F, Richert S, Thiersé D, Van Dorsselaer A, Leize-Wagner E, Raul F, Klein JP, Schöller-Guinard M: Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S. bovis). Carcinogenesis 2004;25:1477–1484.
12.
Gupta A, Madani R, Mukhtar H: Streptococcus bovis endocarditis, a silent sign for colonic tumour. Colorectal Dis 2010;12:164–171.
13.
Abdulamir AS, Hafidh RR, Mahdi LK, Al-jeboori T, Abubaker F: Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. BMC Cancer 2009;9:403.
14.
Schlegel L, Grimont F, Ageron E, Grimont PA, Bouvet A: Reappraisal of the taxonomy of the Streptococcus bovis/Streptococcus equinus complex and related species: description of Streptococcus gallolyticus subsp. gallolyticus subsp. nov., S. gallolyticus subsp. macedonicus subsp. nov. and S. gallolyticus subsp. pasteurianus subsp. nov. Int J Syst Evol Microbiol 2003;53:631–645.
15.
Abdulamir AS, Hafidh RR, Bakar FA: Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol Cancer 2010;9:249.
16.
Marteau P: Bacterial flora in inflammatory bowel disease. Dig Dis 2009;27(suppl 1):99–103.
17.
Rosenstiel P, Sina C, Franke A, Schreiber S: Towards a molecular risk map – recent advances on the etiology of inflammatory bowel disease. Semin Immunol 2009;21:334–345.
18.
Wehkamp J, Stange EF: Is there a role for defensins in IBD? Inflamm Bowel Dis 2008;14(suppl 2):S85–S87. Erratum in: Inflamm Bowel Dis 2009;15:1438–1447.
19.
Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, Glimcher LH: Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007;131:33–45.
20.
Bentley RW, Keenan JI, Gearry RB, Kennedy MA, Barclay ML, Roberts RL: Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn’s disease and control subjects. Am J Gastroenterol 2008;103:1168–1172.
21.
Kirkwood CD, Wagner J, Boniface K, Vaughan J, Michalski WP, Catto-Smith AG, Cameron DJ, Bishop RF: Mycobacterium avium subspecies paratuberculosis in children with early-onset Crohn’s disease. Inflamm Bowel Dis 2009;15:1643–1655.
22.
Sibartie S, Scully P, Keohane J, O’Neill S, O’Mahony J, O’Hanlon D, Kirwan WO, O’Mahony L, Shanahan F: Mycobacterium avium subsp. paratuberculosis (MAP) as a modifying factor in Crohn’s disease. Inflamm Bowel Dis 2010;16:296–304.
23.
Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 2004;127:412–421.
24.
Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel JF, Darfeuille-Michaud A: CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007;117:1566–1574.
25.
Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al: Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut 2003;52:237–242.
26.
Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N, Guarner F, Malagelada JR: Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol 2008;103:643–648.
27.
Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J: Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006;55:205–211.
28.
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731–16736.
29.
Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005;43:3380–3389.
30.
Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J: Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009;15:1183–1189.
31.
Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y: Active Crohn’s disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008;14:147–161.
32.
Rowan F, Docherty NG, Murphy M, Murphy B, Calvin Coffey J, O’Connell PR: Desulfovibrio bacterial species are increased in ulcerative colitis. Dis Colon Rectum 2010;53:1530–1536.
33.
Preidis GA, Versalovic J: Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009;136:2015–2031.
34.
Marteau P, Sokol H, Dray X, Seksik P: Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? Gastroenterol Clin Biol 2009;33 (suppl 3):S228–S234.
35.
Holubar SD, Cima RR, Sandborn WJ, Pardi DS: Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010;6:CD001176.
36.
Prantera C, Lochs H, Gionchetti P, Campieri M, Danese S, Fogli M, Scribano M, Grimaldi M: Rifaximin-EIR (extended intestinal release) 400 mg tablets in the treatment of moderately active Crohn’s disease: results of the international, multicentre, randomised, double-blind, placebo-controlled trial RETIC (abstract). Gut 2010;59(suppl 111)A1.
37.
Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al: Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856–861.
38.
Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617–1623.
39.
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59–65.
40.
Lakhdari O, Cultrone A, Tap J, Gloux K, Bernard F, Ehrlich SD, Lefèvre F, Doré J, Blottière HM: Functional metagenomics: a high throughput screening method to decipher microbiota-driven NF-ĸB modulation in the human gut. PLoS One 2010;5:10.
41.
Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, Ugarte E, Muñoz-Tamayo R, Paslier DL, Nalin R, Dore J, Leclerc M: Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009;11:2574–2584.
42.
Ehrlich DS, MetaHIT Consortium: Metagenomics of the intestinal microbiota: potential applications. Gastroenterol Clin Biol 2010;34(suppl 1):S23–S28.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.